Nitric oxide in gingival crevicular fluid and nitric oxide synthase expression in the gingiva of patients with sickle cell disease by Esra Güzeldemir et al.
115 Research Article  
Nitric oxide in gingival crevicular fluid and 
nitric oxide synthase expression in the gingiva 
of patients with sickle cell disease
Orak hücre anemili hastaların dişetlerindeki nitrik oksit sentetaz 
ekspresyonu ve dişeti oluğu sıvılarındaki nitrik oksit 
düzeyinin değerlendirilmesi
Esra Güzeldemir1, Hilal Uslu Toygar2, Nebil Bal3, Ruksan Anarat4, Can Boğa5
1Department of Periodontology, Faculty of Dentistry, Kocaeli University, Kocaeli, Turkey
2Department of Periodontology, Faculty of Dentistry, Baskent University, Ankara, Turkey
3Department of Pathology, Faculty of Medicine, Baskent University, Ankara, Turkey
4Department of Biochemistry, Faculty of Medicine, Baskent University, Ankara, Turkey
5Department of Hematology, Faculty of Medicine, Baskent University, Ankara, Turkey
Address for Correspondence: Assoc. Prof. Esra Güzeldemir, Department of Periodontology, Faculty of Dentistry, Kocaeli University, 
Yuvacık Yerleşkesi, Yuvacık, Başiskele 41190 Kocaeli, Turkey  Phone: +90 262 344 22 22 E-mail: esragd@yahoo.com
doi:10.5152/tjh.2011.27
Abstract
Objective: This study aimed to biochemically measure the production of nitric oxide in gingival crevicu-
lar fluid and immunohistochemically measure the expression of inducible nitric oxide synthase in the 
gingiva of patients with sickle cell disease. Additionally, we aimed to obtain insight into the immunopa-
thology of sickle cell disease by comparing inducible nitric oxide synthase levels in patients with sickle 
cell disease and controls using gingiva and gingival crevicular fluid. 
Materials and Methods: The study included 20 sickle cell disease patients and 20 healthy controls. 
Immunohistochemical analysis was used to measure inducible nitric oxide synthase expression in gingiva 
and nitric oxide levels in gingival crevicular fluid were spectrophotometrically measured. 
Results:  Nitric  oxide  levels  in  the  patients  and  controls  did  not  differ  significantly  (21.2±4.5  and 
23.1±2.3 μM L-1, respectively, p>0.05). There weren’t any statistically significant differences in infil-
trated inflammatory cells, density of inflammatory cells that stained with inducible nitric oxide synthase, 
or nitric oxide expression in gingiva between the patient and control groups (p>0.05). 
Conclusion: To the best of our knowledge this is the first study to examine the expression of inducible 
nitric oxide synthase in the gingiva and gingival crevicular fluid in patients with sickle cell disease. Using 
the gingiva and gingival crevicular fluid we were unable to observe sickle cell disease-associated inducible 
nitric oxide synthase expression and a difference in nitric oxide levels. 
(Turk J Hematol 2011; 28: 115-24)
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Sickle cell disease (SCD) is the result of hemo-
globin  S  homozygosity,  which  causes  rigid  sickle 
erythrocytes. Interactions between abnormal rigid 
erythrocytes and the vascular wall result in endo-
thelial  activation,  which  may  lead  to  endothelial 
damage  and  tissue  ischaemia  in  SCD.  Chronic 
inflammation during both the steady state and vaso-
occlusive crisis occurs via the action of cytokines 
and other inflammatory factors [1-4]. The clinical 
manifestations of the disease, such as painful cri-
ses,  anemia,  bone  necrosis,  and  leg  ulceration, 
arise  due  to  chronic  hemolysis,  vaso-occlusion, 
ischemia, and tissue damage.
Nitric oxide (NO) is a short-lived free radical that 
influences physiological processes in virtually every 
tissue and is derived from L-arginine via the action 
of constitutive NO synthase (NOS) or inducible NO 
synthase (iNOS), whose activity is induced in sev-
eral cell types, including human gingival fibroblasts. 
iNOS expression results in increased production of 
NO  and  is  activated  during  cellular  distress,  sys-
temic inflammation, hypoxia, and oxidative stress. 
NO is a molecule involved in vascular regulation, 
homeostasis, bone formation and resorption, neu-
rotransmission, and immune function. It plays a role 
in host defense response to infection in oral tissues 
[5].  NO  mediates  physiologic  processes  in  the 
immune,  inflammatory,  nervous,  cardiovascular, 
and pulmonary systems. 
In  infection  and  the  resultant  inflammatory 
responses, NO plays a dual role: it is a central medi-
ator of host response, but also is an important agent 
in the pathogenesis of host damage [6]. Decreased 
levels of L-arginine, and consumption of NO by cell-
free  plasma  hemoglobin  and  by  reactive  oxygen 
species (ROS) appear to impair NO bioavailability, 
resulting in oxidative damage. Because SCD is asso-
ciated with oxidative stress, increased expression of 
endothelial cell adhesion molecules, and blood cell 
adhesion,  which  are  characteristic  features  of  an 
inflammatory  response,  several  researchers  have 
studied the role of iNOS in SCD [7].
The intermittent vascular occlusion that occurs 
in  SCD  leads  to  ischemia-reperfusion  injury  and 
activation  of  inflammatory  processes,  including 
enhanced production of ROS and increased expres-
sion of iNOS. Increased iNOS expression and a con-
sequent increase in tissue nitrite and nitrate produc-
tion have been observed in the kidneys and liver of 
SCD  patients  [8],  mice  [2,3,8,9],  and  pigs  [4]. 
Additionally, it was shown that iNOS inhibition sig-
nificantly  limits  tissue  ischemia-reperfusion  injury 
in the liver and kidneys [10,11]; however, inhibition 
of iNOS attenuated ischemia-reperfusion injury in 
the rat heart [12] and did not affect ischemia-reper-
fusion injury in the rat lung [13]. Increased levels of 
iNOS  expression  were  shown  in  the  kidneys  of 
transgenic mice [9], but Nath et al. [14] reported the 
lack of upregulation of iNOS in the intrarenal vascu-
lature  and  increased  expression  of  iNOS  in  the 
Özet
Amaç: Çalışmamızda, orak hücre anemili hastaların, dişeti dokusunda immünohistokimyasal yöntemle 
nitrik oksit sentetaz ekspresyonunun ve dişeti oluğu sıvısında biyokimyasal yöntemle nitrik oksit düzeyi-
nin değerlendirilmesi amaçlanmıştır.
Yöntemler ve Gereçler: Çalışmaya, 20 orak hücre anemili hasta ve her yönden sağlıklı 20 kontrol kişi 
alınmıştır. Dişeti dokusundaki nitrik oksit sentetaz ekspresyonu immünohistokimyasal yöntemlerle, dişe-
ti oluğu sıvısındaki nitrik oksit düzeyi ise spektrofotometrik yöntemlerle ölçülmüştür. 
Bulgular: Hasta ve kontrol gruplarında, dişeti oluğu sıvısındaki nitrik oksit düzeyleri arasında istatistik-
sel olarak anlamlı bir fark bulunmamıştır (21.2±4.5 ve 23.1±2.3 μM L-1, p>0.05). Gruplar arasında, 
inflamatuvar hücre yoğunluğu, nitrik oksit sentetazla boyanan inflamatuvar hücrelerin yoğunluğu ve 
nitrik oksitle boyanan bu hücrelerde görülen ekspresyonun yoğunluğu açısından anlamlı bir fark görül-
memiştir (p>0.05). 
Sonuç: Araştırmalarımıza göre, bu çalışma, orak hücre anemili hastaların dişeti dokusunda ve dişeti 
oluğu sıvısında nitrik oksit düzeyini ve nitrik oksit sentetaz ekspresyonunu değerlendiren ilk çalışmadır. 
Çalışmamızda dişeti dokularında ve dişeti oluğu sıvısında, orak hücre anemisi ile ilişkili olarak, farklı 
nitrik oksit düzeyleri ve ekspresyonu görülmemiştir. (Turk J Hematol 2011; 28: 115-24)
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of iNOS and its expression seems to vary by organ.
In addition, NO metabolites (NOx; nitrate [NO3-] 
and nitrite [NO2-]) in SCD were evaluated in blood 
samples  in  vivo  [15-17]  and  in  vitro  [18].  It  was 
reported that NOS activity plays a role in stimulating 
production of NOx. iNOS was observed in dental tis-
sues, and increased iNOS production was reported 
in gingival crevicular fluid (GCF) [19] and gingival 
tissues [20-23] in different periodontal diseases, but 
iNOS activity was not observed in the gingival tis-
sues  in  sterile  animals  [24].  Periodontal  diseases 
are inflammatory disorders that cause tissue dam-
age and loss via the complex interactions between 
pathogenic  bacteria  and  host  immune  response. 
Oxidative stress also plays a role in the pathogene-
sis of periodontal diseases; this causes an imbal-
ance between the antioxidant and pro-oxidant sys-
tems. ROS and reactive nitrogen species (NO, NO-
2, 
and ONOO-) are also contributors to this process. 
NO  synthesis  and  iNOS  activity  increase  in 
inflamed periodontal tissues [20,25-28] as a result of 
macrophage infiltration in periodontal tissues [29]. 
The literature includes only a few studies that evalu-
ated  iNOS  activity  in  inflamed  periodontal  tissues. 
iNOS  activity  was  reported  to  increase  in  ligature-
induced periodontitis [27], experimental periodonti-
tis [30], and chronic periodontitis [20,26,31]. Higher 
levels of iNOS expression were observed in chronic 
periodontitis tissues than in clinically healthy gingival 
tissues [20,23,26,27,31] and a previous study of ours 
showed that iNOS increased in the gingival tissue of 
aggressive periodontitis patients (unpublished data). 
In various animal models iNOS was susceptible to 
infections by a variety of pathogens [32-35]. It was 
shown that NO plays an important role in the patho-
genesis  of  chronic  inflammation  [36].  iNOS  is 
expressed  almost  exclusively  during  inflammatory 
conditions, which has led to the hypothesis that iNOS 
has detrimental effects on inflamed tissues and pro-
motes the inflammatory response [37]. 
While  data  regarding  dental  and  periodontal 
conditions is SCD patients are limited, there are no 
data regarding NO levels and the presence/expres-
sion of iNOS in the gingival tissues and GCF of SCD 
patients. GCF is inflammatory exudates that can be 
easily collected from gingival crevices of teeth by 
means of paper strips. Host cell-derived inflamma-
tory tissue response and bacterial products in GCF 
were  assessed  in  studies  related  to  markers  of 
pathogenesis and the diagnosis of periodontal dis-
ease [38]. 
To the best of our knowledge the present study is 
the first to examine NO levels and the presence/
expression  of  iNOS  in  the  gingiva  and  GCF  of 
patients with SCD. Findings regarding NO levels and 
the  expression  of  iNOS  in  different  tissues  and 
organs in SCD patients are inconsistent. The role of 
iNOS  and  its  expression  appears  to  vary  in  each 
organ in patients with SCD. It is well documented 
that iNOS is expressed in inflamed gingiva in differ-
ent  conditions  and  diseases.  Ongoing  chronic 
inflammatory  reactions  in  SCD  patients  result  in 
increased  iNOS  expression;  therefore,  the  aim  of 
the present study was to evaluate NO levels and the 
presence/expression of iNOS in the gingival tissues 
and GCF in SCD patients, as well as to obtain insight 
into  the  immunopathology  of  SCD  in  gingiva  and 
and GCF, in terms of iNOS metabolism. 
Methods
Study population
This study was conducted at Başkent University, 
Adana  Medical  and  Research  Center  between 
January  and  August  2007.  The  Başkent  University 
Ethics Committee (D-KA07/01) approved the study 
protocol.  Samples  were  evaluated  at  Başkent 
University,  Adana  Medical  and  Research  Center, 
Departments of Pathology and Biochemistry. All the 
participants provided informed consent. Evaluation 
of each participant consisted of personal, medical, 
and dental history, and panoramic radiographs and 
dental  examinations.  The  inclusion  criterion  was 
age ≥18 years.
The study included 20 homozygous SCD patients 
in the steady stae that had not received blood trans-
fusions  in  the  preceding  3  months.  The  patients’ 
genotypes were confirmed by electrophoresis. The 
SCD  patients  were  seen  regularly  at  the  Başkent 
University Hematology Clinic. As part of a standard 
medical  examination  they  were  sent  to  the 
Department of Periodontology for dental and peri-
odontal examination and consultation.
The  control  group  included  20  age-  and  sex-
matched  volunteers  without  a  history  of  SCD. 
Exclusion criteria were as follows: history of hepatitis, 
HIV infection, or diabetes, requirement for antibiotic 
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use of anti-inflammatory drugs. All the participants 
were  free  of  systemic,  and  dental  and  periodontal 
diseases. Both groups consisted of non-smokers.
GCF sampling and analysis
Assessment of total NO metabolites (NOx: nitrate 
[NO3-] and nitrite [NO2-]) is commonly used as a 
measure of NO production in biologic fluids. GCF 
samples were obtained using standard paper strips 
(Periopaper, Ora Flow Inc., NY, USA ) following iso-
lation of the tooth with cotton rolls and removal of 
any supragingival deposits on tooth surfaces. The 
collection  region  was  gently  air-dried  for  2  s  to 
reduce  any  contamination  by  plaque  and  saliva. 
The strip was left at the entrance of the gingival sul-
cus for 30 s. GCF volume was calculated using a 
Periotron  8000  (Periotron  8000,  Pro  Flow  Inc., 
Amityville, NY, USA ) device, which was pre-calibrat-
ed with a dry, sterile strip. Samples with evidence of 
bleeding were not included. After volume determi-
nation,  GCF  samples  were  placed  in  sterile 
Eppendorf tubes that were wrapped securely and 
stored at -20°C until analyzed. The same periodon-
tist (E.G.) performed all clinical GCF sampling.
Quantification of nitrate/nitrite content in GCF
There are numerous direct and indirect analyti-
cal methods for the quantification of NO in aqueous 
solutions, but only a few are applicable to biological 
fluids, as NO is highly reactive, has a short half-life 
in vivo, and is produced in small quantities in cells. 
The method used in the present study is based on 
the  quantification  of  the  stable  end  products  of 
nitric oxide-nitrate and nitrite. Nitrate determination 
requires  chemical  and  enzymatic  reduction  to 
nitrite. This method is easy, quick, inexpensive, and 
more  sensitive  (to  micromolar  range)  than  other 
methods [39]. 
To each GCF sample in an Eppendorf tube was 
added 130 µL of distilled water. The samples were 
mixed to extract nitrate into the water. To measure 
nitrate  levels  100  µL  of  the  extract  was  obtained 
from  the  mixture  and  evaluated  using  the  nitrite/
nitrate colorimetric test (Nitrite/Nitrate Colorimetric 
Test, Roche, Germany). The colorimetric reaction 
was allowed to proceed for 10 min at room tem-
perature, and then the optical density (absorbance, 
OD) at 540 nm was measured at room temperature 
using a spectrophotometer (Elisa, Merck, Germany). 
The measured OD values were converted to con-
centrations using a standard curve established by 
the  serial  dilution  of  nitrate.  Analyses  were  per-
formed on coded samples by 1 of the authors (R.A.) 
that was blinded to the participants’ diagnoses.
Gingival biopsy collection and analysis
The  patients  underwent  gingival  biopsy  under 
local  anesthesia.  Local  anesthetic  agent  without 
adrenalin was administered following application of 
a topical anesthetic agent. An inverse bevel incision 
was used to obtain tissue from the underside of the 
papilla. After washing with sterile 0.15 M saline solu-
tion, gingival biopsy specimens were fixed in 10% 
formalin  solution  and  sent  to  the  Pathology 
Department.  Gingival  tissue  biopsy  samples  were 
collected by the same periodontist (E.G.) and analy-
ses were performed on coded samples by another 
author (N.B.) that was blinded to the participants’ 
diagnoses.
After routine paraffin tissue procedures, tissues 
were embedded in paraffin blocks. Then, 4-5-µm 
thick  sections  were  obtained  from  the  paraffin 
blocks,  and  serial  sections  were  immunostained 
with  an  AEC  (3-amino-9-ethylcarbazole)  substrate 
system  and  biotin-streptavidin  complex  system 
(3-amino-9-ethyl-carbazole  [AEC]+ready-to-use 
substrate-chromogen K3469, DAKO, Denmark). AEC 
is a widely used chromogen for immunohistochem-
ical  staining.  Deparaffinization  and  rehydration  of 
the sections were followed by blocking endogenous 
peroxidase activity via incubation of the sections in 
3% H2O2 for 30 min at room temperature. After rins-
ing with distilled water the sections were treated in 
a microwave oven with 10 mM citrate buffer (pH 
6.0) at 500°C for 5 min, 600°C for 4 min, and then 
700°C for 3 min for antigen retrieval. The slides were 
left to cool at room temperature for 50 min. After 
rinsing with phosphate-buffered saline (PBS) for 2-3 
min the slides were kept in 3% H2O2 for 20 min, and 
then rinsed with PBS for 5 min. Non-specific binding 
was  reduced  with  protein  blocking  serum  for  20 
min.  Sections  were  incubated  with  iNOS  primary 
polyclonal antibody (ready-to-use rabbit polyclonal 
antibody RB-1605-R7, Lab-Vision, CA, USA) at room 
temperature overnight. After rinsing with PBS for 2-3 
min the sections were incubated with biotinylated 
goat  antipolyvalent  (Thermo  Scientific  Lab  Vision 
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tions  were  then  washed  with  PBS  for  2-3  min, 
treated with streptavidin peroxidase (ready-to-use 
TS-060-HR, Thermo Scientific, Lab Vision, Fremont, 
CA, USA) for 20 min, and washed with PBS for 2-3 
min. To visualize antibody binding a biotin-streptav-
idin complex system was used, followed by wash-
ing with distilled water, and then the sections were 
counterstained with Mayer’s hematoxylin.
Immunohistochemical slides were used for mor-
phological identification of neutrophils, lymphocytes, 
and  macrophages.  Immunohistochemical  slides 
were examined for positive staining using light micros-
copy. Inflammation in each case was rated according 
to a modified scoring system [40-41] shown in Table 
1, as follows: no inflammation (0), minimal inflam-
mation (1), mild inflammation (2), moderate inflam-
mation  (3),  and  diffuse  inflammation  (4).  In  all,  5 
high-power  fields  (40×  magnification)  per  patient 
and control sample were examined, and the percent-
age  of  inflammatory  cells  expressing  iNOS  was 
scored as 0 (0%-1%), 1 (2%-20%), 2 (21%-50%), and 3 
(≥51%).  In  addition,  the  intensity  of  staining  was 
evaluated, as follows: 0 (absent), 1 (weak), 2 (strong). 
Because AEC was used as a color reagent, orange-
brown staining in cytoplasm was considered as posi-
tive for iNOS activity in inflammatory cells.
Statistical analysis 
Statistical analyses were performed using SPSS 
v.11.0 for Windows (Statistical Product and Service 
Solutions,  SSPS  Inc,  Chicago,  IL,  USA).  Normality 
was  analyzed  using  the  Shapiro-Wilk  test.  The 
Mann-Whitney  U  test  and  independent  samples  t 
test was used to compare differences between the 
patients and controls. Spearman's rank correlation 
coefficient  was  used  to  analyze  the  relationships 
between all parameters. P values <0.05 were con-
sidered statistically significant.
Results
In all, 20 homozygous SCD patients in the steady 
state and 20 healthy age- and sex-matched controls 
without a history of SCD were evaluated. 
Determination of NO production 
Total  NO  end  metabolites  (NOx:  nitrate  [NO3-] 
and nitrite [NO2-]) were quantified in the GCF of 20 
patients  with  SCD  and  20  controls.  NOx  in  GCF 
ranged from 4.45 to 29.37 µM L-1 in SCD patients and 
17.81 to 27.88 µM L-1 in the controls. Mean NO con-
centration  in  GCF  was  higher  in  the  controls 
(23.1±2.3 µM L-1) than in the SCD patients (21.2±4.5 
µM L-1); the difference was not statistically signifi-
cant  (p=0.098)  (Table  2).  Sampling  volume  was 
33.9±21.2 µL in the SCD patients and 25.8±11.1 µL 
in  the  controls;  a  significant  difference  was  not 
observed (p=0.139).
Assessment of iNOS expression
In total, 37 gingival biopsy tissue specimens were 
evaluated for iNOS levels and expression; 17 from 
SCD  patients  and  20  from  controls.  Inflammation 
intensity,  density  of  iNOS(+)  inflammatory  cells, 
and  iNOS  expression  were  measured  (Table  1). 
Inflammation  intensity  indicates  the  intensity  of 
inflammatory cell infiltration, iNOS expression indi-
cates the level of iNOS expression in iNOS-expressed 
inflammatory cells, and density of iNOS(+) inflam-
matory cells is the percentage of cells expressing 
iNOS [31].
All tissues from both groups had few, but evident 
inflammatory  cells  present  in  connective  tissue. 
There  weren’t  any  differences  in  inflammation 
intensity,  percentage  of  cells  expressing  iNOS,  or 
iNOS expression intensity between the patient and 
Table 1. Evaluation of gingival biopsy specimen sections
Inflammation    Density of iNOS (+)    iNOS
Intensity    Inflammatory Cells    Expression
Absent  0  Absent  0  Absent  0
Minimal  1  <20%  1  Weak  1
Slight  2  20%-50%  2  Strong  2
Moderate  3  ≥51%  3   
Diffuse  4       
Table 2. Volume and concentration of total NO products (nitrite/nitrate) 
in the SCD patients and controls 
  SCD Patients  Controls  p
  (n=20)  (n=20)
  mean±SD   mean±SD
  median (range)  median (range) 
Concentration (µM L-1)  21.2±4.5   23.1±2.3  0.098
  21.69  22.85 
  (14.45-29.37)  (17.81-27.88)
Sample volume (µ L-1)  33.9±21.2   25.8±11.1  0.139
  32.50 (8-100)  22.50 (11-55)
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tochemical parameters were strongly correlated in 
the SCD group (inflammation intensity and density 
of  iNOS(+)  inflammatory  cells:  r=0.604,  p<0.05; 
inflammation  intensity  and  iNOS  expression: 
r=0.609,  p<0.01;  iNOS  expression  and  density  of 
iNOS(+) inflammatory cells: r=0.979, p<0.001) and 
in  the  control  group  (inflammation  intensity  and 
density  of  iNOS(+)  inflammatory  cells:  r=0.669, 
p<0.01;  inflammation  intensity  and  iNOS  expres-
sion: r=0.741, p<0.001; iNOS expression and den-
sity  of  iNOS(+)  inflammatory  cells:  r=0.943, 
p<0.001) (Table 4). 
In the present study immunohistochemical stain-
ing  of  the  samples  obtained  from  SCD  patients 
(Figure  a)  and  controls  (Figure  b)  confirmed  the 
lack of inflammatory iNOS-expressing cells in con-
nective  tissue  (40×  magnification).  Stained  cells 
were scattered in the connective tissues. Some of 
the basal layer of epithelium cells exhibited sparse 
positive staining.
Discussion
To the best of our knowledge the present study is 
the first to examine the NO level in the gingiva and 
the  presence/expression  of  iNOS  in  GCF  in  SCD 
patients. The present findings indicate that NO lev-
els  and  iNOS  expression  in  SCD  patients  did  not 
significantly differ from those in the controls.
iNOS expression was observed in chronic inflam-
matory diseases of the airway, blood vessels, bowel, 
kidneys, heart, skin, and gingiva. It was suggested 
that the serum NO level is elevated in megaloblastic 
anemia [42] and that the plasma NO level in beta-
thalassemia minor patients is low at the time of diag-
nosis [43]. In addition, excessive salivary NO plays a 
potential role in modifying oral mucosal diseases, as 
a  physiopathological  regulator  [44].  Many  recent 
studies have reported increased NO production in 
Table 3. Median inflammation intensity, density of iNOS(+) inflamma-
tory cells, and iNOS expression in the SCD patients and controls
  SCD Patients   Controls  p
  (n=17)  (n=20)
  median (range)  median (range) 
Inflammation intensity   2.0 (0-4)  1.0 (0-4)  0.964
Density of iNOS (+)   0.0 (0-2)  0.5 (0-2)  0.537
inflammatory cells  
iNOS expression   0.0 (0-2)  0.5 (0-2)  0.641
Table 4. Correlation between tissue specimen immunohistochemical 
parameters in the SCD patients and controls
    Density of   iNOS
    iNOS (+)   expression
    inflammatory cells   
SCD Patients  Inflammation   0.604*  0.609**
  intensity 
  Density of iNOS (+)     0.979***
  inflammatory cells   
Controls  Inflammation   0.669**  0.741***
  intensity 
  Density of iNOS (+)     0.943***
  inflammatory cells   
Significant correlations: *p<0.05, **p<0.01,Significant correlations: *p<0.05, 
**p<0.01, ***p<0.001, ***p<0.001
Figure 1. Immunohistochemical staining of SCD patient (A) and control tissues (B) confirmed the lack of inflammatory iNOS-expressing 
cells in connective tissue (40× magnification)
A B
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been implicated in the pathogenesis of apical infec-
tion [45], periapical granulomas [46], and inflamed 
human dental pulp [47]. Increased iNOS expression 
in gingiva was shown in periodontitis [20,22,26,28,31], 
ligature-induced  periodontitis  [27],  experimental 
periodontitis [30,46], inflamed gingiva [23], localized 
aggressive  periodontitis  [21],  and  recently  by  our 
group in aggressive periodontitis (unpublished data). 
Increased  levels  of  NO  in  diabetic-periodontitis 
patients were observed in GCF [19]. Accordingly, we 
previously  observed  that  inflammation  and  iNOS 
expression were higher in the gingiva of patients with 
both diabetes and periodontitis [48].
iNOS expression has been reported in a variety of 
pathogenic states characterized by oxidative stress, 
and  inflammation  and/or  ischemic  reperfusion 
[7,49]. SCD is also strongly associated with oxida-
tive stress, increased expression of endothelial cell 
adhesion molecules, and blood adhesion. Increased 
iNOS  expression  and  NO  production  have  been 
observed in the kidneys and the liver in SCD patients 
[8],  in  mice  [2,3,8,9],  and  in  pigs  [4].  During  the 
clinically asymptomatic state, NO bioavailability is 
reduced in SCD patients due to scavenging of NO by 
cell-free  hemoglobin  released  from  hemolyzed 
sickle  erythrocytes  [50]  and  increased  arginase 
activity  [51].  During  NO  synthesis  by  NOS,  if 
L-arginine levels decrease or consumption of NO 
increases via cell-free plasma hemoglobin and ROS, 
then oxidative damage occurs, HbS denatures, and 
superoxide production increases. It was shown that 
iNOS inhibition significantly limits tissue ischemia-
reperfusion injury in the liver and kidneys [10-11]; 
however,  inhibition  of  iNOS  attenuated  ischemia-
reperfusion injury in the rat heart [12], but not in the 
rat lung [13]. Increased iNOS expression was report-
ed in the kidneys of transgenic mice [9], but Nath et 
al. [14] reported the lack of iNOS upregulation in 
intrarenal vasculature and increased iNOS expres-
sion  in  the  glomeruli  and  distal  tubules  of  sickle 
mice. Previous attempts to demonstrate increased 
iNOS expression in SCD-affected tissues have yield-
ed inconclusive results [52-55].
NO  reacts  with  oxygen,  forming  nitrite  (NO2-) 
and nitrate (NO3-). These oxidative metabolites of 
NO-referred to as NOx-are often used as surrogate 
markers of NO production because of their instabil-
ity in oxygenated environments. A deficient plasma 
concentration  in  microcirculation  promotes  pro-
longed  vascular  transit  time.  In  a  clinical  study 
plasma  NOx  concentrations  in  steady-state  SCD 
patients were significantly higher than in controls 
and there was no difference compared to the onset 
of painful crises [16]. Lopez et al. [56] studied adult 
SCD patients with vaso-occlusive crises and report-
ed that both plasma arginine and NOx levels were 
significantly lower in the SCD patients than in the 
controls. NOx levels in children that presented dur-
ing  vaso-occlusive  crisis  were  similar  to  baseline 
levels [57], in contrast to Lopez et al.’s [58] finding 
of  low  NOx  levels  in  adults  during  vaso-occlusive 
crisis. Most studies on NOx evaluated the effects of 
different treatment modalities in SCD patients. 
Although  oral  problems  have  been  described  in 
SCD patients, they are not as common as other medi-
cal  problems.  Oral  problems,  including  unilateral 
infarct of the mandible [59,60], pulpal necrosis [59,61], 
osteonecrosis [62], facial swelling [63], diastema and 
hypodontia [64], gingival enlargement [63], palatal pal-
lor [65], increased risk for caries [66], osteomyelitis of 
the mandible [67], unilateral anesthesia [60,62], midfa-
cial  overgrowth  [65],  and  orofacial  pain  [65,67,68], 
have been reported [69]. As iNOS activity and expres-
sion are strongly correlated with immune and inflam-
matory systems, to eliminate the likelihood of conflict-
ing results in the present study only participants that 
were free of clinically detectable infection and inflam-
mation were included; the participants had no ongoing 
dental, periodontal, or orofacial disorders. 
There are conflicting findings regarding NO lev-
els  and  iNOS  expression  in  different  tissues  and 
organs in SCD patients. This may be because NO 
bioavailability is controlled by several mechanisms, 
such as NO scavenging by plasma hemoglobin and 
superoxide, arginine concentration and availability 
by plasma arginase, NO inactivation via ROS derived 
from xanthine oxidase, NADPH oxidase, hemoglo-
bin S and auto-oxidation, iNOS mRNA stability, post 
translational modification, presence of endogenous 
inhibitors of NOS activity, and local concentrations 
of  arginase-inhibiting  compounds  [49,70].  Thusly, 
NO bioavailability and iNOS expression, and their 
roles seem to vary by organ and sometimes vary in 
different regions of the same organ.
In conclusion, the present findings indicate that 
NO levels and iNOS expression in the gingiva and 
GCF  in  SCD  patients  did  not  differ  from  those  in 
Güzeldemir et al.
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the role of iNOS in different tissues in SCD patients.
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